StockData
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3029% below fair value
$1.91+0.10 (+5.52%)

Close on Nov 17, 2026Market cap $22.11MP/E –Yield –

TherapeuticsMD operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

TherapeuticsMD's operating cash flow for the twelve months ending Jun 30, 2026 was $3.10M, up 201.9% year over year. For fiscal 2025 it was $2.45M, up 109.7% from the year before. The highest annual figure on record is $9.36M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.45M+109.7%
FY2024Dec 31, 2024$1.17M–
FY2023Dec 31, 2023-$23.08M-346.6%
FY2022Dec 31, 2022$9.36M–
FY2021Dec 31, 2021-$55.13M–
FY2020Dec 31, 2020-$159.47M–
FY2019Dec 31, 2019-$165.72M–
FY2018Dec 31, 2018-$106.81M–
FY2017Dec 31, 2017-$76.16M–
FY2016Dec 31, 2016-$69.14M–
FY2015Dec 31, 2015-$79.04M–
FY2014Dec 31, 2014-$45.52M–
FY2013Dec 31, 2013-$20.77M–
FY2012Dec 31, 2012-$12.74M–
FY2011Dec 31, 2011-$4.97M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$779.00K+104.5%
Q1 FY2026Mar 31, 2026$944.00K+35.1%
Q4 FY2025Dec 31, 2025$375.00K+2105.9%
Q3 FY2025Sep 30, 2025$999.00K–
Q2 FY2025Jun 30, 2025$381.00K-73.8%
Q1 FY2025Mar 31, 2025$699.00K–
Q4 FY2024Dec 31, 2024$17.00K–
Q3 FY2024Sep 30, 2024-$71.00K–
Q2 FY2024Jun 30, 2024$1.45M–
Q1 FY2024Mar 31, 2024-$229.00K–
Q4 FY2023Dec 31, 2023-$4.96M-116.4%
Q3 FY2023Sep 30, 2023-$6.03M-134.0%
Q2 FY2023Jun 30, 2023-$3.39M–
Q1 FY2023Mar 31, 2023-$8.70M–
Q4 FY2022Dec 31, 2022$30.24M-37.0%
Q3 FY2022Sep 30, 2022$17.72M–
Q2 FY2022Jun 30, 2022-$20.72M–
Q1 FY2022Mar 31, 2022-$17.87M–
Q4 FY2021Dec 31, 2021$48.00M–
Q3 FY2021Sep 30, 2021-$38.22M–
Q2 FY2021Jun 30, 2021-$26.53M–
Q1 FY2021Mar 31, 2021-$38.38M–
Q4 FY2020Dec 31, 2020-$30.36M–
Q3 FY2020Sep 30, 2020-$34.05M–
Q2 FY2020Jun 30, 2020-$55.95M–
Q1 FY2020Mar 31, 2020-$39.11M–
Q4 FY2019Dec 31, 2019-$50.82M–
Q3 FY2019Sep 30, 2019-$26.22M–
Q2 FY2019Jun 30, 2019-$50.51M–
Q1 FY2019Mar 31, 2019-$38.16M–
Q4 FY2018Dec 31, 2018-$28.14M–
Q3 FY2018Sep 30, 2018-$34.07M–
Q2 FY2018Jun 30, 2018-$24.95M–
Q1 FY2018Mar 31, 2018-$19.65M–
Q4 FY2017Dec 31, 2017-$20.81M–
Q3 FY2017Sep 30, 2017-$16.68M–
Q2 FY2017Jun 30, 2017-$18.14M–
Q1 FY2017Mar 31, 2017-$20.53M–
Q4 FY2016Dec 31, 2016-$15.62M–
Q3 FY2016Sep 30, 2016-$18.80M–

More TherapeuticsMD figures

See a number that looks wrong?